Cell Research

A experimental drug study contraposing common gene mutation in melanoma ,confirmed that the drug dabrafenib successfully shrink the tumor lesions of melanoma in patients with brain metastases, the effective rate reaches to 90%. The result of this international Phase I clinical drug trials published in an internationally renowned journal The Lancet, in the May 18. BRAF gene encodes a serine / threonine protein kinase B-Raf, which is closely related to cell growth regulation. In melanoma, BRAF mutations often cause disorders of cell growth regulation. Dabrafenib plays a role in mutant type BRAF - Val600. In order to confirm its safety and tolerability and provide dose reference for phase II trials in clinical, the researchers recruited 184 patients with solid tumors for test, including 156 patients with metastatic melanoma. According to the accelerated dose titration method, after systematic Dabrafenib treatment, the researchers found no cases of treatment discontinuation and death due to drug side-effect. Moreover, Dabrafenib also has anti-cancer effects on other BRAF mutation-type solid tumors, such as gastrointestinal solid tumors, non-small cell lung cancer, ovarian cancer, and so on